Chemotherapy

Interferon-α-2b as an adjuvant therapy prolongs survival of patients with previously resected oral muscosal melanoma

R. Wang, Jing, G., Lv, J., Song, H., Li, C., Wang, X., Xia, W., Wu, Y., Ren, G., and Guo, W., Interferon-α-2b as an adjuvant therapy prolongs survival of patients with previously resected oral muscosal melanoma, vol. 14, pp. 11944-11954, 2015.

Two major subtypes of melanoma include cutaneous melanoma and mucosal melanoma. The latter type is rare and usually occurs in the head and neck region. High-dose interferon-α-2b (IFN-α-2b) has proven effective in the treatment of cutaneous melanoma. Recently, a regimen of temozolomide plus cisplatin was reported more likely to improve relapse-free survival and overall survival than high-dose IFN-α-2b for mucosal melanoma. We conducted this study to analyze the therapeutic effect of high-dose IFN-α-2b for patients with oral mucosal melanoma who had received prior chemotherapy.

Subscribe to Chemotherapy